Rimmel London Announces Adwoa Aboah As New Global Brand Activist
USA - English
Share this article
Share this article
LONDON, May 6, 2021 /PRNewswire/ Rimmel London is proud to announce international model and mental health advocate, Adwoa Aboah, as the new global activist for the beauty brand.
Celebrating bold individualism, Adwoa will be the face of major beauty campaigns and product launches throughout 2021 and beyond. Adwoa and Rimmel London are like-minded in advocating self-expression and believe in the freeing power of makeup, not to transform but to empower all wearers.
Adwoa Aboah for Rimmel London (PRNewsfoto/Rimmel London)
Born and raised in London, Adwoa began modelling at the age of 18 and landed her first VOGUE cover at the age of 22. Having modelled for some of the world s most internationally renowned and iconic fashion houses, Adwoa now joins a long list of trailblazing women who have previously been the face of Rimmel London, including Kate Moss, Georgia Ma
Share this article
Share this article
NEW YORK, May 6, 2021 /PRNewswire/ Around the world, 463 million adults had diabetes in 2019, and by 2045, this number is expected to rise to 700 million, as per the International Diabetes Federation (IDF). Similarly, the incidence of cancer, chronic obstructive pulmonary disease (COPD), asthma, and heart diseases, is rising. This factor will likely propel the global market for prefilled syringes from $1,914.1 million in 2020 to $3,646.7 million by 2030, at a 6.8% CAGR between 2021 and 2030, according to P&S Intelligence.
Such diseases require a regular administration of drugs, for which prefilled syringes are increasingly being used. In this regard, the rising usage of injectable pharmaceutical drugs is also driving the prefilled syringes market growth, since parenteral administration is one of the quickest ways of getting the drug to the target area inside the body. Prefilled syringes minimize drug wastage and the infection risk, thus pr
Share this article
Share this article
ORLANDO, Fla., May 5, 2021 /PRNewswire/ Board-certified emergency medicine physician Dr. JB is pleased to announce the official launch of her new
YouTube channel. In her weekly video uploads, Dr. JB delivers straightforward medical information to viewers without using the usual confusing medical jargon. The timing of the launch comes in response to the year-long pandemic that frightened the world and put medicine at the forefront of everyone s mind, no matter how healthy. Putting a focus on typical emergency medical needs, and other general medical information, Dr. JB s YouTube channel speaks directly to the patient s perspective.
Share this article
Share this article
HANGZHOU and SHAOXING, China, May 4, 2021 /PRNewswire/ Ascletis Pharma Inc. (HKEX:1672) today announces the positive Phase IIa clinical results of ASC22 (Envafolimab), which is a first-in-class, subcutaneously administered PD-L1 antibody for chronic hepatitis B (CHB) functional cure.
ASC22 Phase IIa clinical trial is a single dose escalation study of three subcutaneously administered doses (0.3, 1.0 and 2.5 mg/kg, three patients per dose) with 12-week follow-up to explore the safety and preliminary efficacy of ASC22 in CHB patients (ClinicalTrials.gov Identifier: NCT04465890). The primary efficacy endpoint is HBsAg reduction during 12-week follow-up after the single dose administration. Median baseline HBsAg of nine CHB patients enrolled was 3.0 log
Frost & Sullivan Recognizes Palo Alto Networks as a Leader in the US Healthcare Cybersecurity Market
News provided by
Share this article
Share this article
Palo Alto Networks, the global cybersecurity leader, is transforming the healthcare industry by enabling the organizations to improve patient and employee experience, protect patient data and improve regulatory compliance throughout the continuum of care
SANTA CLARA, Calif., May 5, 2021 /CNW/ Frost & Sullivan has identified Palo Alto Networks as a growth and innovation top-performing leader in the
Frost Radar™: US Healthcare Cybersecurity Market, 2020.
The company s solutions are used by a myriad of health systems ranging from hospitals with a seemingly less complicated mix to integrated delivery network (IDNs) catering to a complex disease mix and experimental treatment with connected care enablers that drive precision medicine workflows. The report states: